(NYSE: RCUS) Arcus Biosciences's forecast annual revenue growth rate of -11.58% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.15%.
Arcus Biosciences's revenue in 2025 is $262,000,000.On average, 14 Wall Street analysts forecast RCUS's revenue for 2025 to be $25,216,691,144, with the lowest RCUS revenue forecast at $23,311,576,673, and the highest RCUS revenue forecast at $27,714,626,150. On average, 14 Wall Street analysts forecast RCUS's revenue for 2026 to be $16,132,807,342, with the lowest RCUS revenue forecast at $6,049,536,676, and the highest RCUS revenue forecast at $33,065,975,624.
In 2027, RCUS is forecast to generate $21,909,880,719 in revenue, with the lowest revenue forecast at $10,555,398,476 and the highest revenue forecast at $37,079,487,729.